Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)

Eleftherios P. Diamandis, Frank Z. Stanczyk, Sarah Wheeler, Anu Mathew, Martin Stengelin, Galina Nikolenko, Eli N. Glezer, Marshall D. Brown, Yingye Zheng, Yen Hao Chen, Hsiao Li Wu, Ricardo Azziz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth-generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-To-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95% confidence interval [CI]: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95% CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-The-receiver-operating-characteristic curve of 0.89. Serum cPSA and fPSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.

Original languageEnglish (US)
Pages (from-to)1789-1797
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Volume55
Issue number11
DOIs
StatePublished - Oct 26 2017

Fingerprint

Polycystic Ovary Syndrome
Prostate-Specific Antigen
Biomarkers
Serum
Hyperandrogenism
Testosterone
Assays
Steroids
Hormones
Body Mass Index
Odds Ratio
Confidence Intervals
Waist-Hip Ratio
Ovulation
ROC Curve
Cross-Sectional Studies

Keywords

  • androgen-regulated genes
  • hirsutism
  • hyperandrogenism
  • polycystic ovarian syndrome
  • prostate specific antigen
  • serum biomarkers
  • urine biomarkers

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Diamandis, E. P., Stanczyk, F. Z., Wheeler, S., Mathew, A., Stengelin, M., Nikolenko, G., ... Azziz, R. (2017). Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clinical Chemistry and Laboratory Medicine, 55(11), 1789-1797. https://doi.org/10.1515/cclm-2016-1124

Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). / Diamandis, Eleftherios P.; Stanczyk, Frank Z.; Wheeler, Sarah; Mathew, Anu; Stengelin, Martin; Nikolenko, Galina; Glezer, Eli N.; Brown, Marshall D.; Zheng, Yingye; Chen, Yen Hao; Wu, Hsiao Li; Azziz, Ricardo.

In: Clinical Chemistry and Laboratory Medicine, Vol. 55, No. 11, 26.10.2017, p. 1789-1797.

Research output: Contribution to journalArticle

Diamandis, EP, Stanczyk, FZ, Wheeler, S, Mathew, A, Stengelin, M, Nikolenko, G, Glezer, EN, Brown, MD, Zheng, Y, Chen, YH, Wu, HL & Azziz, R 2017, 'Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)', Clinical Chemistry and Laboratory Medicine, vol. 55, no. 11, pp. 1789-1797. https://doi.org/10.1515/cclm-2016-1124
Diamandis, Eleftherios P. ; Stanczyk, Frank Z. ; Wheeler, Sarah ; Mathew, Anu ; Stengelin, Martin ; Nikolenko, Galina ; Glezer, Eli N. ; Brown, Marshall D. ; Zheng, Yingye ; Chen, Yen Hao ; Wu, Hsiao Li ; Azziz, Ricardo. / Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). In: Clinical Chemistry and Laboratory Medicine. 2017 ; Vol. 55, No. 11. pp. 1789-1797.
@article{42b170d1f17f4a50943e6b60904f6681,
title = "Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)",
abstract = "Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth-generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-To-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95{\%} confidence interval [CI]: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95{\%} CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-The-receiver-operating-characteristic curve of 0.89. Serum cPSA and fPSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.",
keywords = "androgen-regulated genes, hirsutism, hyperandrogenism, polycystic ovarian syndrome, prostate specific antigen, serum biomarkers, urine biomarkers",
author = "Diamandis, {Eleftherios P.} and Stanczyk, {Frank Z.} and Sarah Wheeler and Anu Mathew and Martin Stengelin and Galina Nikolenko and Glezer, {Eli N.} and Brown, {Marshall D.} and Yingye Zheng and Chen, {Yen Hao} and Wu, {Hsiao Li} and Ricardo Azziz",
year = "2017",
month = "10",
day = "26",
doi = "10.1515/cclm-2016-1124",
language = "English (US)",
volume = "55",
pages = "1789--1797",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "11",

}

TY - JOUR

T1 - Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)

AU - Diamandis, Eleftherios P.

AU - Stanczyk, Frank Z.

AU - Wheeler, Sarah

AU - Mathew, Anu

AU - Stengelin, Martin

AU - Nikolenko, Galina

AU - Glezer, Eli N.

AU - Brown, Marshall D.

AU - Zheng, Yingye

AU - Chen, Yen Hao

AU - Wu, Hsiao Li

AU - Azziz, Ricardo

PY - 2017/10/26

Y1 - 2017/10/26

N2 - Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth-generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-To-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95% confidence interval [CI]: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95% CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-The-receiver-operating-characteristic curve of 0.89. Serum cPSA and fPSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.

AB - Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth-generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-To-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95% confidence interval [CI]: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95% CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-The-receiver-operating-characteristic curve of 0.89. Serum cPSA and fPSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.

KW - androgen-regulated genes

KW - hirsutism

KW - hyperandrogenism

KW - polycystic ovarian syndrome

KW - prostate specific antigen

KW - serum biomarkers

KW - urine biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85028019901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028019901&partnerID=8YFLogxK

U2 - 10.1515/cclm-2016-1124

DO - 10.1515/cclm-2016-1124

M3 - Article

C2 - 28361781

AN - SCOPUS:85028019901

VL - 55

SP - 1789

EP - 1797

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 11

ER -